For the melanoma cohort, 78% of patients had a diagnosis of cutaneous melanoma with BRAF wild type status (BRAF is the most commonly altered genetic alteration in melanoma and used for treatment decisions), and most patients were treated with combination anti-PD-1 and anti-CTLA-4. Here, CTLA4 is linked to cutaneous melanoma.